---
document_datetime: 2023-09-21 20:16:20
document_pages: 38
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/plegridy-h-c-2827-x-56-epar-assessment-report-variation_en.pdf
document_name: plegridy-h-c-2827-x-56-epar-assessment-report-variation_en.pdf
version: success
processing_time: 27.5156468
conversion_datetime: 2025-12-20 15:09:00.657031
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

15 October 2020 EMA/CHMP/594296/2020 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Plegridy

International non-proprietary name: peginterferon beta-1a

Procedure No. EMEA/H/C/002827/X/0056

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................6                                 |                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................6      |                                                                                                        |
| 1.2. Steps taken for the assessment of the product.........................................................6               |                                                                                                        |
| 2. Scientific discussion                                                                                                   | ................................................................................7                      |
| 2.1. Problem statement                                                                                                     | ...............................................................................................7       |
| 2.1.1. Disease or condition...........................................................................................8    |                                                                                                        |
| 2.1.2. Epidemiology and risk factors..............................................................................8        |                                                                                                        |
| 2.1.3. Aetiology and pathogenesis                                                                                          | ................................................................................8                      |
| 2.1.4. Clinical presentation, diagnosis and prognosis                                                                      | .......................................................8                                               |
| 2.1.5. Management.....................................................................................................8    |                                                                                                        |
| 2.2. Quality aspects                                                                                                       | ....................................................................................................9  |
| 2.2.1. Introduction......................................................................................................9 |                                                                                                        |
| 2.2.2. Active Substance.............................................................................................10     |                                                                                                        |
| 2.2.3. Finished Medicinal Product                                                                                          | ................................................................................10                     |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................13                       |                                                                                                        |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                  | ......................14                                                                               |
| 2.2.6. Recommendations for future quality development................................................14                    |                                                                                                        |
| 2.3. Non-clinical aspects                                                                                                  | ............................................................................................14         |
| 2.4. Clinical aspects                                                                                                      | ..................................................................................................14   |
| 2.4.1. Introduction....................................................................................................14  |                                                                                                        |
| 2.4.2. Pharmacokinetics.............................................................................................15     |                                                                                                        |
| 2.4.3. Pharmacodynamics..........................................................................................21        |                                                                                                        |
| 2.4.4. Discussion on clinical pharmacology...................................................................23            |                                                                                                        |
| 2.4.5. Conclusions on clinical pharmacology.................................................................24             |                                                                                                        |
| 2.5. Clinical efficacy                                                                                                     | ..................................................................................................24   |
| 2.5.1. Discussion on clinical efficacy............................................................................24       |                                                                                                        |
| 2.5.2. Conclusions on the clinical efficacy.....................................................................25         |                                                                                                        |
| 2.6. Clinical safety                                                                                                       | ....................................................................................................25 |
| 2.6.1. Discussion on clinical safety                                                                                       | ..............................................................................30                       |
| 2.6.2. Conclusions on the clinical safety.......................................................................31         |                                                                                                        |
| 2.7. Risk Management Plan                                                                                                  | ........................................................................................31             |
| 2.8. Pharmacovigilance..............................................................................................33     |                                                                                                        |
| 2.9. Product information                                                                                                   | ............................................................................................33         |
| 2.9.1. User consultation.............................................................................................33    |                                                                                                        |
| 3. Benefit-Risk Balance..............................................................................33                    |                                                                                                        |
| 3.1. Therapeutic Context                                                                                                   | ...........................................................................................33          |
| 3.1.1. Disease or condition.........................................................................................33     |                                                                                                        |
| 3.1.2. Available therapies and unmet medical                                                                               | need.......................................................33                                          |
| 3.1.3. Main clinical study                                                                                                 | ...........................................................................................34          |
| 3.2. Favourable effects                                                                                                    | ..............................................................................................34       |
| 3.3. Uncertainties and limitations about favourable effects.............................................34                 |                                                                                                        |
| 3.4. Unfavourable effects...........................................................................................34     |                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | .........................................35                                                            |

<div style=\"page-break-after: always\"></div>

3.6. Effects Table  ......................................................................................................  35

3.7. Benefit-risk assessment and discussion  .................................................................  36

3.7.1. Importance of favourable and unfavourable effects  ..............................................  36

3.7.2. Balance of benefits and risks  .............................................................................  36

3.7.3. Additional considerations on the benefit-risk balance ...........................................  36

3.8. Conclusions .......................................................................................................  36

4. Recommendations .................................................................................  37

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

Adverse Event

ANOVA

Analysis of variance

AUC0- ∞

Area under the concentration-time curve from hour 0 extrapolated to infinity

AUC0-336

Area under the concentration-time curve from hour 0 to hour 336

AUC0-504

Area under the concentration-time curve from hour 0 to hour 504

AUC0-last

Area under the concentration-time curve from hour 0 to the last measurable concentration

AUC0-t

Area under the concentration-time curve from hour 0 to the last observed concentration at time t

BD

Becton Dickinson

BLQ

Below the Limit of Quantification

bpm

Beats per minute

BL/GF

Break-Loose force and Glide Force

BMI

Body Mass Index

BIIB017

Peginterferon beta-1a

CHMP

Committee for Medicinal Products for Human Use

CI

Confidence Interval

CL/F

Apparent total body clearance

Cmax

Maximum observed concentration

CNS

Central Nervous System

CRU

Clinical Research Unit

CV

Coefficient Variation

DMD

Disease Modifying Drug

EDSS

Expanded Disability Status Scale

EAUC0-336

Effect-time curve from time zero to 336 hours postdose

EAUC0-504

Effect-time curve from time zero to 504 hours postdose

Ebaseline

Baseline concentration

EMA

European Medicines Agency

Epeak

Maximum effect

ETmax

Time to reach Maximum effect

GCP

Good Clinical Practice

cGMP

current Good Manufacturing Practice

IFN β

Beta interferon

IM

Intramuscular

ISRs

Injection site reaction

LL

Luer Lock

LLOQ

Lower Limit of Quantification

λZ

Terminal elimination rate constant

MA

Marketing Authorisation

MAH

Marketing Authorisation Holder

MS

Multiple Sclerosis

Nabs

Neutralizing antibodies

%AUCextrap

Percentage extrapolation of AUC ∞

PD

Pharmacodynamics

PEG

Polyethylene Glycol

PFS

Pre-filled syringe

PIP

Paediatric Investigation Plan

PK

Pharmacokinetics

<div style=\"page-break-after: always\"></div>

| PPQ   | Process Performance Qualification                                 |
|-------|-------------------------------------------------------------------|
| PRAC  | Pharmacovigilance Risk Assessment Committee                       |
| QCs   | Quality Control samples                                           |
| RRMS  | Relapsing-Remitting Multiple Sclerosis                            |
| SC    | Subcutaneously                                                    |
| SD    | Standard deviation                                                |
| SmPC  | Summary of Product Characteristics                                |
| TEAEs | Treatment-Emergent Adverse Events                                 |
| T max | Time to maximum observed concentration                            |
| T 1/2 | Terminal elimination half-life                                    |
| tQC   | Trending quality control                                          |
| Vd/F  | Apparent volume of distribution during terminal elimination phase |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

Biogen Netherlands B.V. submitted on 10 February 2020 an extension of the marketing authorisation (MA).

Extension application to introduce a new route of administration (intramuscular use) for the 125 µg solution for injection.

The  Marketing  Authorisation  Holder  (MAH)  applied  for  a  change  or  addition  of  a  new  route  of administration.

## The legal basis for this application refers to:

Article 19 of Commission Regulation (EC) No 1234/2008 and Annex I of Regulation (EC) No 1234/2008, (2) point(e) - Extensions of marketing authorisations

## Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0371/2019 on the agreement of a paediatric investigation plan (PIP)

At  the  time  of  submission  of  the  application,  the  PIP  P/0371/2019  was  not  yet  completed  as  some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Johann Lodewijk Hillege Co-Rapporteur:  N/A

| The application was received by the EMA on                                     | 10 February 2020   |
|--------------------------------------------------------------------------------|--------------------|
| The procedure started on                                                       | 27 February 2020   |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on | 25 May 2020        |

<div style=\"page-break-after: always\"></div>

| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                      | 26 May 2020       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 11 June 2020      |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                                                        | 26 June 2020      |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                            | 17 July 2020      |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                  | 18 August 2020    |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 04 September 2020 |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the MAH on                                                                        | 17 September 2020 |
| The MAH submitted the responses to the CHMP List of Outstanding Issues on                                                                                                                | 18 September 2020 |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                         | 01 October 2020   |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Plegridy on | 15 October 2020   |

## 2. Scientific discussion

## 2.1. Problem statement

Plegridy  is  an  interferon  beta-1a  with  a  prolonged  response  (due  to  Polyethylene  Glycol  [PEG] conjugation). It is indicated in adult patients for the treatment of relapsing-remitting multiple sclerosis (RRMS).

The recommended dose of Plegridy is 125 micrograms injected subcutaneously (SC) every 2 weeks. The product may be self-administered by patients.

The product is available as a 63, 94 and 125 micrograms strength, both in a pre-filled syringe and a prefilled pen. The lower strengths are used for dose titration at the start of treatment, to prevent flu-like symptoms.

The  current  application  concerns  an  extension  application.  The  MAH  proposes  to  add  intramuscular injection (IM) to offer patients an alternative route of administration with fewer injection site reactions (ISRs) as compared to subcutaneous injection.

A new pre-filled syringe has been developed for this purpose. The syringe contains 125 micrograms of peginterferon beta-1a. The dose can be limited to 63 micrograms and 94 micrograms with the use of titration clips.

<div style=\"page-break-after: always\"></div>

## 2.1.1. Disease or condition

Plegridy is indicated in adult patients for the treatment of RRMS.

## 2.1.2. Epidemiology and risk factors

Multiple  sclerosis  (MS)  is  a  chronic  disease  of  the  central  nervous  system  (CNS)  with  a  worldwide prevalence estimated at 2 to 2.5 million patients. The disease is unevenly distributed throughout the world; its prevalence varies between &lt;5 cases per 100,000 people in tropical areas and Asia and &gt;100 to  200  cases  per  100,000  in  temperate  areas,  especially  those  with  large  populations  of  Northern European origin.

The worldwide incidence of MS is estimated to be 3.6 cases per 100,000 person-years in women (95% confidence interval [CI] 3.0-4.2) and 2.0 cases per 100,000 person-years in men (95% CI 1.5-2.4) [Alonso and Hernan 2008]. Therefore, MS is approximately twice as common in women as men and predominantly affects adults aged 20 to 60 years.

A genetic predisposition to MS exists, particularly variation involving the HLA-DRB1 locus [Lincoln 2005; Sawcer 2011]. Risk is elevated if a family member has MS [Ebers 2008]. Risk of MS increases with increasing geographic latitude. Vitamin D deficiency has been found to significantly increase the risk of developing MS, so reduced sunlight exposure during childhood at higher latitudes may be an explanation for the geographic phenomenon [Ascherio and Munger 2007].

## 2.1.3. Aetiology and pathogenesis

The aetiology of MS is unknown, the synergic effect of genetic and environmental factor leads to immunemediated inflammatory activity of the CNS that lead to destruction of the myelin sheath and axonal injury.

## 2.1.4. Clinical presentation, diagnosis and prognosis

MS can present with a range of neurological symptoms depending on the category of disease and location of the lesions, but commonly reported symptoms in established, untreated MS are visual dysfunction, weakness, which is frequently lower limb, sensory symptoms, and bladder problems, and progressive ambulatory decline will affect a sizable proportion of patients with MS. Diagnosis of MS is based on clinical presentation together with the findings in the magnetic resonance imaging [Mc Donald 2001, 2010, 2017].

RRMS is the most common form of MS, representing approximately 85% of patients at diagnosis. The course of RRMS is unpredictable, with variable periods of disease activity interspersed with periods of stability. According to earlier natural history studies, approximately 40% and 25% of patients with RRMS will, within the first 15 years after diagnosis, need to use a walking aid and be wheelchair-dependent [Myhr 2001]. Recent findings  from  cohorts  of  patients  mostly  treated  with  disease  modifying  drugs (DMDs) from early onset have found lower transition rates to secondary progressive MS.

## 2.1.5. Management

There  is  no  cure  available  for  MS.  Therapies  for  MS  include  treatment  for  relapses  (e.g.  steroids), symptomatic treatments (e.g. drugs for stabilization of nerve conduction, drugs for managing fatigue, depression, pain) and those that alter the course of the disease (DMDs).

<div style=\"page-break-after: always\"></div>

There  are  several  DMD  for  MS  including  beta  interferons  ( IFN  β )  (Avonex,  Betaferon  and  Rebif), glatiramer  acetate  (Copaxone),  teriflunomide  (Aubagio),  dimethyl  fumarate  (Tecfidera),  fingolimod (Gilenya), siponimod (Mayzent), ozanimod (Zeposia) , alemtuzumab (Lemtrada), natalizumab (Tysabri), ocrelizumab (Ocrevus), cladribine (Mavenclad).

## About the product

Plegridy  is  a  PEG-modified  interferon  beta-1a  (Company  Code:  BIIB017)  that  is  approved  for  the treatment of RRMS.

BIIB017 binds to the type I interferon receptor on the surface of cells and elicits a cascade of intracellular events leading to the regulation of interferon-responsive gene expression. Biological effects that may be mediated by BIIB017 include up-regulation of anti-inflammatory cytokines (e.g. IL-4, IL-10, IL-27), down-regulation  of  pro-inflammatory  cytokines  (e.g.  IL-2,  IL-12,  IFNγ,  TNF -α)  and  inh ibiting  the migration of activated T cells across the blood brain barrier. However, the full/definitive mechanism of action for BIIB017 is not known, as the pathophysiology of MS is only partially understood.

## Type of Application and aspects on development

This dossier concerns a line extension application for Plegridy (peginterferon beta-1a) to add IM injection as an additional route of administration for the adult population. Peginterferon beta-1a is administered every 2 weeks via SC injection and is approved for RRMS in adults. The basis for this application is an open-label, multicentre, 2-period crossover study (105HV106) to assess the bioequivalence of BIIB017 administered by SC and IM injection in healthy volunteers.

Existing IFN β on the market are available for either SC or IM injection. The approval of BIIB017 for IM administration  will  provide  patients  with  an  alternative  route  of  administration  along  with  the convenience of less frequent IM dosing seen with a pegylated interferon compared with a non-pegylated interferon. In addition, data from the literature show that the IM administration of IFN β -1a resulted in fewer ISRs than the SC route [Balak 2012; Minagara 2008].

## 2.2. Quality aspects

## 2.2.1. Introduction

The current application concerns a line extension for Plegridy to be administered via the IM route as addition to the current MA for Plegridy, which is administered SC for RRMS. Besides the different route of administration, Plegridy for IM and SC administration share the same indication, posology, composition and formulation.

The active substance of Plegridy is peginterferon beta-1a, herein referred to as BIIB017. BIIB017 prefilled syringe (PFS) for IM injection will only be manufactured in the administration dose strength of 125 μg (micrograms) per syringe.

The only differences between the BIIB017 PFS for IM injection and the approved BIIB017 PFS for SC injection are:

- (1) the new finished product manufacturing site with slightly adapted manufacturing process,
- (2) the container closure; a 1 mL Becton Dickinson (BD) Luer Lock (LL) syringe, instead of a 1 mL staked needle syringe

<div style=\"page-break-after: always\"></div>

- (3) the co-packaged needle (23G, 1.25 ʺ stainless steel), instead of staked needle (29G, 0.5'stainless steel)
- (4) the method of titration utilising titration clip devices, which control the administered dose to ½ and ¾ of the administration dose syringe, instead of availability of administration dose strength of 63 and 94 μg.

## 2.2.2. Active Substance

There were no changes made to this section as the same active substance (BIIB017-B) is used to produce BIIB017 delivered IM or SC.

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical Development

The BIIB017 finished product is a sterile, liquid formulation in a PFS for IM injection cont aining 125 μg of peginterferon beta-1a. Other excipients are: sodium acetate trihydrate; acetic acid, glacial; arginine hydrochloride; polysorbate 20 and water for injections. No novel excipients are used.

BIIB017  PFS  for  IM  injection  is  supplied  in  a  sterile  1  mL  Type  I  borosilicate  glass  syringe  with  a bromobutyl rubber plunger stopper and OVS tamper-evident seal. BIIB017 is filled into the PFS at a nominal volume of 0.5 mL. The intended dosage form for use by the patient consists of the PFS with 125 μg  strength  for  titration  and  administration  dosing.  Titration  of  the  dose  during  the  first  month  of treatment is controlled with titration clip devices.

## Pharmaceutical Development

Composition of the PFS finished product for IM use is identical to the already approved PFS for SC use. The same active substance (BIIB017-B) and the same excipients are used to produce BIIB017 delivered IM or SC.

Development of BIIB017 finished product for IM injection included transfer of the BIIB017 manufacturing process to with a slightly adapted manufacturing process. Minor changes are introduced in the filtration step, the finished product filling and the component preparation step:

-  A filter flush was implemented prior to filtration as process improvement in the bioburden reduction filtration on bulk finished product.
-  Due to differences in hold up volume between SC and IM needles, a slightly higher target fill volume is utilised in the IM process. This is to ensure that the target dose is delivered with the larger IM needle and Luer Lock syringe hold-up volume.
- Closure of LL syringe is required (tamper-evident seal - OVS).

The differences between the manufacturing processes at the current manufacturer for SC syringes and new manufacturer for IM syringes are well described.

Comparability  between  the  manufacturing  process  for  PFS  for  IM  injection  and  the  manufacturing process  for  PFS  for  SC  injection  has  been  shown  by  comparing  the  release  data  and  additional characterisation of subvisible particulate matter of three process performance qualification (PPQ) batches PFS for IM injection with historical ranges of 76 PFS batches for SC injection.

<div style=\"page-break-after: always\"></div>

Results show that the IM finished product is comparable with the SC finished product, with the exception of extractable volume. Extractable volume is slightly higher for IM batches due to the higher fill volume target. Due to differences in hold up volume between SC and IM needles, a slightly higher target fill volume is utilised in the IM process. This is to ensure that the target dose is delivered with the larger IM needle and Luer Lock syringe hold-up volume.

The differences between the container closure system for the PFS for IM injection and the PFS for SC injection are differences in the needle (difference in length and gauge required for IM presentation) and differences in the closure. The Luer Lock syringe requires tamper evident seal and LL connection and tip cap. Suitability of the container closure system has been shown by container closure integrity testing, extractables and leachables studies and functionality testing.

Container closure integrity testing was performed during process validation, shipping qualification and long-term storage.

Data of extractables and leachables studies for the materials in contact with the finished product were submitted. The presented results do not raise any safety concerns.

The results of functional testing were provided. Functionality studies at stability conditions up to 48 months (at 5°C); up to 9 months (at 25°C) and up to 6 months (at 40°C) are ongoing.

The low doses (63 and 94 μg) will be administered by the use of titration clip devices. The CE -marked medical  devices  are  supplied  as  Titration  Kit  in  a  separate  package.  Information  on  design  and performance of these titration clip devices has been provided. The administration of the correct doses, as mentioned in the Summary of product characteristics (SmPC), using these titration clip devices has been shown in dose accuracy studies.

The MAH did not perform a traditional human factor study, however a comparative usability assessment was performed against the AVOSTARTGRIP® device, i.e. an already available titration clip device for administration of IFN β .

The MAH has changed the artwork for the carton exterior, packaging and package leaflet to clearly distinguish between the SC and IM formulation. Furthermore, the physical presentations of the products differ. Therefore, the probability of occurrence of administration of incorrect medication in the titration phase (confusion between the IM and SC formulation) is assessed as 'low'.

## Manufacture of the product and process controls

Plegridy IM PFS finished product is manufactured, released, stored, labelled, and packaged in accordance with  current  Good  Manufacturing  Practice  (cGMP).  The  manufacturing  of  BIIB017  finished  product consists of the following steps:

- Step 1: Compounding of Formulation Buffer
- Step 2: Thawing of the Bulk Drug Substance
- Step 3: Pooling and Mixing
- Step 4: Addition of Formulation Buffer to Achieve Target Protein Concentration and Formulation
- Step 5: Filtration into Dispensing Vessel
- Step 6: Sterile Filtration to the Filling Line
- Step 7: Aseptic Syringe Filling and Plunger Placement

<div style=\"page-break-after: always\"></div>

- Step 8: 100% Visual Inspection
- Step 9: Finished product storage

The manufacturing process has been well described. The process controls and control of critical steps and intermediates are the same as for the SC manufacturing process and are acceptable.

Process evaluation consisted of the production of three PPQ batches in which several hold times were challenged. Finished product release assays were performed on the filled LL syringes, and the results were  compared  to  the  release  specification  and  historic  database  for  the  licensed  BIIB017  finished product administered SC.

The results confirm that the finished product manufacturing process for BIIB017 finished product for IM injection at is validated.

## Product specification, analytical procedures, batch analysis

The finished product specification includes tests for identity, quantity, potency (by antiviral cytopathic effect assay), purity and safety.

The specifications for BIIB017 PFS for IM injection specifications are identical to or tighter than the specifications for BIIB017 PFS for SC injection. The specifications for protein concentration, oxidation and biantennary sialylation are tightened as a result of re-evaluation of the specifications for BIIB017 PFS for SC injection. The information provided in this section is sufficient and acceptable.

## Analytical procedures

Except for container closure integrity testing as sufficiently detailed in the dossier, all analytical methods are the same as for the BIIB017 finished product for SC injection. The method validations have been adequately summarized.

## Batch analysis

The release test results for the PPQ lots of BIIB017 finished product for IM injection have been provided. A summary of the lots, their manufacturing history, and purpose of use have been presented.

All results met the release specifications, demonstrating the quality and consistency of the commercial manufacturing process.

## Stability of the product

A shelf life of 36 months when stored at 2 ° C to 8 ° C is claimed for the finished product.

Based on the stability data presented the same shelf-life (36 months at 5 ° C with an allowance of storage for up to 30 days at room temperature (not to exceed 25 ° C) within the 36-month shelf life) has been claimed  for  BIIB017  finished  product  for  IM  injection  as  is  currently  approved  for  BIIB017  finished product for SC injection.

The applicant has submitted a comparative stability evaluation of IM and SC presentations demonstrating that both presentations behave similar upon storage and therefore the same shelf-life is considered acceptable for commercial lots BIIB017 PFS for IM injection as is currently approved for BIIB017 PFS for SC injection.

<div style=\"page-break-after: always\"></div>

A shelf life of 36 months when stored at 2 ° C to 8 ° C is acceptable for the finished product. Plegridy for SC or IM administration can be stored at room temperature (up to 25 °C) for up to 30 days protected from light, after this period it should be discarded.

## Post approval change management protocol(s)

Not applicable.

## Adventitious agents

Plegridy active substance is the same for Plegridy SC and IM. There are no process changes/differences in the active substance, hence Virology testing is the same as what is currently registered in section 3.2.A Adventitious Agents Safety Evaluation for Plegridy SC MAA.

No changes were made to this section.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

The current application concerns a line extension for Plegridy to be administered via the IM route as addition to the current MA for Plegridy, which is administered SC for RRMS.

Besides the different route of administration, Plegridy for IM and SC administration share the same indication,  posology  and  formulation.  BIIB017  PFS for  IM  injection  will  only  be  manufactured  in  the administration dose strength of 125 μ g per syringe.

The differences between the BIIB017 PFS for IM injection and the approved BIIB017 PFS for SC injection were justified and adequately discussed.

Composition of the PFS finished product for IM use is identical to the already approved PFS for SC use. The same active substance (peginterferon beta-1a, BIIB017-B) is used to produce BIIB017 delivered IM or SC.

Comparability  between  the  manufacturing  process  for  PFS  for  IM  injection  and  the  manufacturing process  for  PFS  for  SC  injection  has  been  shown  by  comparing  the  release  data  and  additional characterisation of subvisible particulate matter of three PPQ batches PFS for IM injection with historical ranges of 76 PFS batches for SC injection. Results show that the IM finished product is comparable with the SC finished product, with the exception of extractable volume. Extractable volume is slightly higher for IM batches due to the higher fill volume target. Due to differences in hold up volume between SC and IM needles, a slightly higher target fill volume is utilised in the IM process. This is to ensure the target dose is delivered with the larger IM needle and Luer Lock syringe hold-up volume.

The differences between the container closure system for the PFS for IM injection and the PFS for SC injection are differences in the needle (difference in length and gauge required for IM presentation) and differences in the closure. The Luer Lock syringe requires tamper evident seal and LL connection and tip cap. Suitability of the container closure system has been shown by container closure integrity testing, extractables and leachables studies and functionality testing.

LL syringes for IM use are washed, siliconised, and sterilised, while the approved syringes for SC use are siliconised and sterilised by the supplier.

The manufacturing process has been well described. Process evaluation consisted of the production of three  PPQ  batches  in  which  several  hold  times  were  challenged.  It  has  been  shown  that  the

<div style=\"page-break-after: always\"></div>

manufacturing process is well controlled. The specifications for BIIB017 PFS for IM injection specifications are identical to or tighter than specifications for BIIB017 PFS for SC injection.

The adventitious agents safety is sufficiently assured, and no changes were made to this section.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The overall quality of this line extension for Plegridy is considered acceptable when used in accordance with the conditions defined in the SmPC. The different aspects of the chemical, pharmaceutical and biological  documentation comply with existing guidelines. The manufacturing process of the finished product has been satisfactorily described and validated. The quality of the finished product is controlled by adequate test methods and specifications.

In conclusion, based on the review of the quality data provided, this line extension application for Plegridy to add the IM route of administration is considered approvable from the quality point of view.

## 2.2.6. Recommendations for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommended some points for further investigation.

## 2.3. Non-clinical aspects

No new non-clinical studies have been submitted to support this extension application.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with Good Clinical Practice (GCP) as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Type of Study        | Study Identifier   | Objective(s) of the Study                                                                               | StudyDesign and Type of Control                         | TestProduct(s); DosageRegimen; Route of Administration       | Number'of Participants (current)   | Healthy Subjects or Diagnosis of Patients   | Duration of Treatnent             | Study Status; Type of Report   |
|----------------------|--------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------------|------------------------------------|---------------------------------------------|-----------------------------------|--------------------------------|
| Bioequi valence (BE) | 105HV106           | EvaluatethePKof BIB017 administeredvia intramuscular (IM) andsubcutaneous (SC) routes of administration | Phase 1, single dose, randomized. open-label, crossover | BIIB017; Onedoseeachof BIB017125mcg SC.administeredIM and SC | 136enrolled: 130completed          | Healthy subjects                            | Subjects dosedon Day 1 and Day 29 | Complete; Full                 |

<div style=\"page-break-after: always\"></div>

## 2.4.2. Pharmacokinetics

Peginterferon beta-1a (or BIIB017) currently approved administration is via SC injection using a singleuse pre-filled pen or pre-filled syringe (available at 3 different concentrations - 64, 94 and 125 µg/0.5 ml). IM administration using a single use pre-filled syringe is being proposed as an alternative route of administration. IM injection will only be manufactured in the dose strength of 125 μg per syringe but with titration clips to deliver the lower doses of 63 and 94 μg.

Study 105HV106 was submitted to support the application with a primary objective of assessing the bioequivalence  of  BIIB017  administered  by  SC  and  IM  injection  in  healthy  volunteers.  Secondary objectives of this study were to evaluate the safety, tolerability, and additional pharmacokinetics (PK) parameters of SC administration as compared with IM administration of BIIB017 in healthy volunteers. In addition, as exploratory objectives, pharmacodynamics (PD) parameters such as neopterin and titre of binding antibodies to the pegylated an d IFN β -1a components of BIIB01 were planned to be evaluated. The latter was not carried out since there were no unusual PK or safety results.

Pharmacokinetics of BIIB017 were characterized previously in the original MAA. During that time a small study (Study 105HV101) in healthy volunteers evaluated PK and PD of BIIB017 following SC and IM administration of a dose of 125 µg BIIB017. Although the findings from that study suggested similar bioavailability following SC and IM administration, no conclusion could be drawn because the sample size was too low (N= 8 subjects per administration). In this report, the PK and PD results of Study105HV106 were described and discussed.

## Methods

## Study design

Study 105HV106 was an open-label, multi-center, 2-period, crossover study to assess the bioequivalence and tolerability of BIIB017 administered by SC and IM injection in healthy volunteers.

According to the MAH, the Investigators obtained institutional review board (IRB, Midlands Independent Review Board, Kansas, USA) approval for the study protocol and all amendments.

The clinical study was conducted in 2 sites of Covance Clinical Research Unit Inc. in the USA (i.e. Daytona Beach, Florida and Dallas, Texas). The date of 1st treatment was on 3 December 2018 and the end of study was on 24 May 2019. The PK-samples were analysed at the BioAgilitix Labs (Durham, NC, USA) on 5 March - 2 July 2019. The PD-samples were analysed at Charles River Laboratories (Quebec, Canada) on 4 April - 29 May 2019. The study report is dated 31 October 2019.

After a screening period of up to 28 days, volunteers reported to the Clinical Research Unit (CRU) on Day -1 of Period 1 (Check-in) and on Day 1 of Period 1, volunteers were randomized 1:1 to treatment sequence 1 or 2. Volunteers were dosed on Day 1 of Period 1 and discharged from the CRU on Day 15 of Period 1. Volunteers returned for outpatient visits on Days 17, 19, and 22 of Period 1. After a washout period of a minimum of 27 days following Day 1 of Period 1, volunteers returned to the CRU on Day -1 of Period 2 (Check-in). Volunteers were dosed on Day 1 of Period 2 and discharged from the CRU on Day 15 of Period 2. Volunteers returned for outpatient visits on Days 17, 19, and 22 of Period 2.

Each volunteer received both of the following treatments administered to the anterolateral thigh:

- Treatment A (test): A single IM dose of 125 μg BIIB017.
- Treatment B (reference): A single SC dose of 125 μg BIIB017.

The study scheme is depicted in Figure 1

<div style=\"page-break-after: always\"></div>

Figure 1: Study Schematic of Crossover Design

<!-- image -->

CRU = Clinical Research Unit; IM = intramuscular; SC = subcutaneous.

Day -1 of Period 2 was to occur 27 (+3) days after Day 1 of Period 1 (dosing) in order that dose administrations occurred 28 (+3) days apart.

## Pharmacokinetics

A total of 23 blood samples were collected for determining the concentrations of BIIB017 at the following time points relative to dosing on Day 1 of each period: within 2 hours prior to dosing and 3, 6, 12, 24, 32, 40, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 384, 432 and 504 hours postdose.

## Pharmacodynamics

The same number and time points of blood samples as in the PK part were collected for determining neopterin serum levels.

## Immunogenicity

Samples to test for the presence and titre of binding antibodies to PEG and IFN ß-1a were collected prior to dosing in each period and at the last outpatient visit on Day 22 of Period 2. These samples were stored to be analysed only in the event of an unexpected PK or safety finding. Since there were no unusual PK or safety results, antibody status was not tested, and no immunogenicity data are available for this study.

## Safety

Clinical assessments were performed to evaluate the safety profile of BIIB017.

## Investigated medicinal product for test and reference for treatment

BIIB017  (20kDa  mPEG-O-2-methylpropionaldehydemodified  human  IFN  β -1a)  was  provided  as  a solution  in  20  mM  acetic  acid/sodium  acetate  buffer  (pH  4.8),  150  mM  arginine  hydrochloride,  and 0.005% Polysorbate 20 in volunteer-specific, labeled, prefilled syringe to deliver 0.5 mL of 0.25 mg/mL BIIB017 (125μg dose).

## Population studied

A total of 136 healthy subjects (61 females and 75 males), aged 21-55 years with a body mass index (BMI) of 19 - 30 kg/m 2  were enrolled and dosed in period 1. Six subjects did not receive BIIB017 in period 2 due to AEs (n=3), non-compliance (n=2) and physician decision (n=1). Thus, 130 subjects (SC=66 and IM=64) were dosed in period 2 and available for PK analysis. In addition, 5 other subjects

<div style=\"page-break-after: always\"></div>

were discontinued from the study due to lost to follow-up (n=1) and subject withdrawal (n=4). Hence, a total of 125 volunteers completed the study according to protocol.

## Analytical methods

## ELISA for measuring BIIB017 levels in serum

For the study samples analysis, the system suitability and performance requirements were met. Global run accuracy and precision ranged from 94.2 to 100% and 8.5 to 10.3%, respectively.

A total of 6,085 samples were analysed. A total of 241 runs were performed, of which 23 (9.5%) failed to  meet  the  acceptance  criteria  (i.e.  incorrect  calibrator  volume,  3/6  Control  Samples  (QCs)  failed, contamination of curve), and the samples were re-assayed on subsequent runs. Twelve additional runs were conducted to evaluate incurred sample re-analysis; of these 12 runs, 2 failed to meet acceptance criteria. These 2 runs were repeated, for a total of 14 sample re-analysis runs.

A total of 274 samples (0.05 % of total samples analysed) was re-analysed due to the following reasons: concentration above upper limit of quantification = 190 samples, concentration measured for a pre-dose sample/repeated due to below the limit of quantification (BLQ) for second re-assay value = 3 samples, BLQ at dilution = 74 samples and others = 9 samples.

For ISR, approximately 10% of the first 1000 samples, then 5% of the samples that exceed the initial 1000 were tested. Individual incurred samples from multiple subjects between the maximum observed concentration (Cmax) and the elimination phase were selected and a total of 372 samples (5%) were analyzed, of which 332 samples (88%) were within 30% of their mean.

## ELISA for measuring neopterin concentration in serum

The  serum  concentration  of  neopterin  following  administration  of  BIIB017  125  μg  IM  and  SC  was measured for PD analysis. Neopterin is a protein that is synthesized by IFNβ activated monocytes and macrophages and is a well-established marker of IFNβ activity [Casoni 2004].

Based on the positive performance of the standards and QCs during sample analysis, the neopterin concentration values reported for the study samples from the ELISA assay were valid.

The actual study samples were analysed in duplicate and sample analysis was repeated if the percentage of  coefficient  variation  (CV)  between  duplicate  drug  concentrations  was  &gt;25%.  Mean  results  were reported and expressed as nmol/l. All study samples were analysed within the validated temperature, freeze/thaw cycles, and long-term storage stabilities.

## Immunogenicity Assessments

Antibody status was not tested as no unusual PK or safety findings were observed.

## Pharmacokinetic data analysis

The  following  PK  parameters  were  calculated  using  non-compartmental  methods  using  Phoenix WinNonlin (Certara, USA, Inc., version 8.1): (primary) Cmax and area under the concentration-time curve from hour 0 extrapolated to infinity (AUC0-∞ ), and (secondary), time to maximum observed concentration (tmax), Area under the concentration-time curve from hour 0 to hour 336 (AUC0-336), hour 504 (AUC0-504), and the last measurable concentration (AUC0-last), percentage extrapolation of AUC ∞ (%AUCextrap), termin al elimination rate constant (λZ), terminal elimination half -life (t1/2), apparent total body clearance (CL/F), and apparent volume of distribution during terminal elimination phase (Vd/F).

All AUCs in PK analysis were calculated using the linear trapezoidal rule and the minimum requirement for the calculation of AUC is the inclusion of at least three consecutive serum concentrations above the

<div style=\"page-break-after: always\"></div>

Lower Limit of Quantification (LLOQ), with at least one of these concentrations following Cmax. Percentage extrapolation greater than 20% were excluded from descriptive and formal statistics.

## Evaluation pharmacodynamic endpoints

Neopterin levels were summarized by treatment group and nominal time point using descriptive statistics for the PD Population. Derived PD parameters including baseline concentration (Ebaseline), area under the effect-time curve from time zero to 336 hours postdose (EAUC0-336), area under the effect-time curve from time zero to 504 hours postdose (EAUC0-504), maximum effect (Epeak), and time to reach maximum effect (ETmax) were summarized using arithmetic mean, standard deviation (SD), CV%, geometric mean and geometric CV%, median, minimum, and maximum by treatment group for the PD Population.

## Evaluation of immunogenicity

No evaluation was done since immunogenicity testing was not performed.

## Statistical methods

The statistical analysis was performed using the software package SAS® 9.4 (SAS Institute Inc., Cary, NC, USA).

A  2-treatment,  2-period  crossover  analysis  of  variance  (ANOVA)  model  was  used  to  estimate  the geometric mean ratios and their CIs. For each primary endpoint (AUC ∞ or Cmax), the model included the endpoint on a log-transformed scale as the dependent variable, with treatment, period, and treatment sequence as fixed effects, and volunteer as the random effect. The estimation was based on restricted maximum likelihood approach. The estimated ratio between treatment groups and the associated 90% CI on the original scale were presented and used to establish bioequivalence. The primary analysis model assumed that volunteers drop out at random, conditional on the fixed and random effects and was based on  the  PK  Population  (volunteers  who  received  both  doses  of  study  treatment  with  sufficient  PK measurements to allow calculation of PK parameters).

As a sensitivity analysis, the above ANOVA analysis was repeated in the Full Analysis (Safety) Population (subjects  who  received  at  least  1  dose  of  study  treatment  and  had  at  least  1  post-baseline  PK measurement) for Cmax, AUC0-∞ and  AUC0-last.  In  addition,  results  of  AUC0-∞ or  Cmax  from  all  study volunteers were summarized by treatment group using descriptive statistics.

The primary parameters AUC0-∞ and Cmax were used to establish bioequivalence of the test treatment to the reference treatment. The 90% CIs for the ratios of geometric means between test and reference were calculated for AUC0-∞ and Cmax using log-transformed data. The bioequivalence was established if the 90% CIs for AUC0-∞ and Cmax were within the range of 80% to 125%.

The PK parameters including tmax, AUC0-336, AUC0-504, AUC0-last , %AUCextrap, λZ, t1/2, CL/F, and Vd/F were  summarized using  arithmetic  mean,  SD,  CV%,  geometric  mean  and  geometric  CV%,  median, minimum, and maximum by treatment group for the PK Population.

## Absorption

## Bioequivalence

The serum concentration of BIIB017 following singles doses of 125 μg BIIB017 SC or 125 μg BIIB017 IM were summarised in Table 1 and Table 2 and illustrated in Figure 2.

The serum concentration versus time profiles  after  single  doses  of  125  μg  BIIB017  SC  and  125  μg BIIB017 IM were similar, with maximal concentrations reached at a median tmax of 40 hours post-dose for SC (range: 11.9 to 312 hours) and 40 hours post-dose for IM (range: 6 to 144 hours) (Table 1). After

<div style=\"page-break-after: always\"></div>

reaching Cmax, the serum concentrations of BIIB017 declined monophasically, with mean t1/2 values of 97.1 hours (29.1 to 239.9 hours) for SC and 79.1 hours (26.3 to 233.3 hours) for IM.

In general, moderate to high between-subject variability was noted for the PK parameters (AUC0-∞, Cmax, and AUC0-last) for both routes of administration, with CV% values ranging from 41% to 57% for SC and 40% to 54% for IM (Table 1).

Geometric mean values for Cmax and AUC0-∞ seemed slightly higher for IM than SC. However, statistical analysis showed that 125 μg BIIB017 SC and 125 μg BIIB017 IM were bioequivalent. Geometric least squares mean ratio (90% CI) of IM versus SC was 1.08 (0.98 to 1.20) for Cmax and 1.09 (1.02 to 1.16) for AUC0-∞ all contained within the 0.80 to 1.25 equivalence range.

The additional sensitivity analysis for AUC0-∞, AUC0-last and  Cmax, based on the Safety Population also showed that all 90% CIs of geometric least squares mean ratio (IM versus SC) were contained within the 0.80 to 1.25 equivalence range (Table 2).

Figure 2:  Arithmetic Mean (±SD) serum concentration-time profiles for BIIB017 (pg/mL) following a single SC and IM dose of 125 μg BIIB017 -PK Population (n = 130)

LinearScale

<!-- image -->

NOTE: Lower limit of quantification=15.6pg/mL. BLQ is treated as 0 for linear scale and missing for semi-logarithmic scale Non-determinable is set to missing

Abbreviations: SC= subcutaneous; IM=intramuscular

Run date

: 14OCT2019

<div style=\"page-break-after: always\"></div>

Table 1: PK parameters of BIIB017 following a single SC and IM dose of 125 μg BIIB017 (non -transformed values; arithmetic mean ± SD, tmax median, range) - PK Population

| Treatment           | AUC0-00 pg/ml/ (N = 124 for SC and 129 for IM)   | AUCo-t pg/ml/h (N=130 for bothSCand IM)   | Cmax pg/ml (N =130 for bothSCand IM)   | tmax hour (N = 124 for SC and 129 for IM)   | t1/2 hour (N = 127 for SC and 130 for IM)   |
|---------------------|--------------------------------------------------|-------------------------------------------|----------------------------------------|---------------------------------------------|---------------------------------------------|
| BIIB017SC (125μg)   | 173512± 70565                                    | 163228± 71765                             | 1461 ± 835                             | 40 (12-312)                                 | 97±33                                       |
| BIIB017IM (125μg)   | 184729 ± 74022                                   | 179851 ± 73676                            | 1502 ± 804                             | 40 (6 -144)                                 | 79 ± 26                                     |
| *Ratio (90% CI)     | 1.09 (1.02 -1.16)                                | 1.13 (1.06 -1.21)                         | 1.08 (0.98 - 1.20)                     | NA                                          | NA                                          |
| Between subjectcv%o | 41 (SC); 40 (IM)                                 | 44 (SC); 41 (IM)                          | 57 (SC); 54 (IM)                       |                                             |                                             |

AUC0-∞: Area under the concentration-time curve from hour 0 extrapolated to infinity

AUC0-t: Area under the concentration-time curve from hour 0 to the last observed concentration at time t

Cmax: Maximum observed concentration

Tmax: Time to maximum observed concentration

T ½: Terminal elimination half-life

SC: Subcutaneous; IM: Intramuscular; CI: Confidence Interval; CV: Coefficient variation

*ln-transformed values geometric mean ratio

Table 2:  Sensitivity analysis for primary PK parameters - Safety population

| Treatment           | AUC0-∞ pq/ml/ (N = 128 for SC and 131 for IM)   | AUCo-t pq/ml/h (N = 134 for SC and 132 for IM)   | Cmax pq/ml (N = 134 for SC and 132 for IM)   |
|---------------------|-------------------------------------------------|--------------------------------------------------|----------------------------------------------|
| BIIB017 SC (125μg)  | 173695 ± 69684                                  | 163615 ± 70925                                   | 1459± 827                                    |
| BIIB017 IM (125μg)  | 185645 ± 75087                                  | 180798 ± 74759                                   | 1517±814                                     |
| *Ratio (90% CI)     | 1.09 (1.02 -1.16)                               | 1.13 (1.06 -1.21)                                | 1.08 (0.98 - 1.20)                           |
| Between subject CV% | 40 (SC); 40 (IM)                                | 43 (SC); 41 (IM)                                 | 57 (SC); 54 (IM)                             |

AUC0-∞: Area under the concentration-time curve from hour 0 extrapolated to infinity

AUC0-t: Area under the concentration-time curve from hour 0 to the last observed concentration at time t Cmax: Maximum observed concentration

SC: Subcutaneous; IM: Intramuscular; CI: Confidence Interval; CV: Coefficient variation

*ln-transformed values geometric mean ratio

## Distribution

N/A

## Elimination

N/A

## Dose proportionality and time dependencies

N/A

Intra- and inter-individual variability

<div style=\"page-break-after: always\"></div>

In general, moderate to high between-subject variability was noted for the PK parameters (AUC0-∞ , Cmax and AUC0-last) for both routes of administration, with CV% values ranging from 41% to 57% for SC and 40% to 54% for IM.

## Special populations

N/A

## Pharmacokinetic interaction studies

N/A

## Pharmacokinetics using human biomaterials

N/A

## 2.4.3. Pharmacodynamics

## Methods

The bioequivalence study described above also had the following exploratory objectives:

- To evaluate PD of SC and IM administration of BIIB017 in healthy volunteers
- To evaluate the immune response to BIIB017

The  serum  concentration  of  neopterin  following  a dministration  of  BIIB017  125  μg  IM  and  SC  was measured for PD analysis. Derived PD parameters included Ebaseline, EAUC0-336, EAUC0-504, Epeak, and ETmax.

The presence of binding antibodies to PEG and the presence and titre of binding antibodies to IFN ß-1a. These samples were collected with the intention of analysing them only in the event of unexpected PK or safety findings.

The PD Population was defined as all randomized volunteers who received at least 1 dose of study treatment with at least 1 PD measurement after baseline. All 136 volunteers were included in the PD Population.

## Results

## Demographics

Seventy-five volunteers were male and 61 were female, all aged between 21 and 55 years. The mean weight and BMI of volunteers was similar for each randomized treatment sequence group with a mean weight (SD) of 77.3 kg (11.93) and 78.7 kg (12.82), and mean BMI (SD) of 26.9 kg/m2 (2.51) and 26.2 kg/m2 (2.80) for treatment sequence of IM/SC and SC/IM, respectively.

## Neopterin

Serum concentrations for neopterin following singles doses of 125 μg BIIB017 SC or 125 μg BIIB017 IM are illustrated in Figure 3. A summary of neopterin parameters is presented in Table 3.

The serum neopterin concentration versus time profiles following single doses of 125 μg BIIB017 SC or 125 μg BIIB017 IM were similar, with maximal concentrations (Epeak) reached at a median ETmax of 40.1 hours and 44.0 hours, respectively. Geometric mean neopterin levels increased from baseline to maximum concentration similarly between the 2 injection routes, with the increase from 8.0 to 22.6 nmol/L for SC, and from 8.1 to 23.2 nmol/L for IM. The overall systemic exposure to neopterin (EAUC0-336 and EAUC0-504) were also similar between the 2 routes of administration.

<div style=\"page-break-after: always\"></div>

In general, moderate to high between-subject variability was noted for the PD parameters (EAUC0-336, EAUC0-504, and Epeak) for both routes of administration, with CV% values ranging from 40% to 43% for SC and 34% to 41% for IM.

Figure  3:  Arithmetic  mean  (+/-SD)  serum  concentration  profiles  for  neopterin  (nmol/L) following a single subcutaneous and intramuscular dose of 125 ug BIIB017 - PD population

<!-- image -->

NOTE:  Lower  limit  of  quantification=4nmol/L.  BLQ  is  treated  as  0  for  linear  scale  and  missing  for  semi-logarithmic  scale.  Nondeterminable is set to missing Abbreviations: SC= subcutaneous; IM=intramuscular

Run date

: 14OCT2019

Table 3: Summary statistics for PD parameters - PD Population

|                                       | (N=134)   | BIIB017 125 ug SC   | BIIB017 125 ug SC   | BIIB017 125 ug IM (N=132)   |
|---------------------------------------|-----------|---------------------|---------------------|-----------------------------|
| E baseline (nmol/L)                   |           |                     |                     |                             |
| n                                     |           | 134                 |                     | 132                         |
| Geometric mean                        | 8.0       |                     | 8.1                 |                             |
| Geometric CV (%)                      |           | 33.8                |                     | 37.4                        |
| Arithmetic mean (SD)                  |           | 8.6 (4.4)           |                     | 8.8 (5.3)                   |
| CV%                                   |           | 51.3                |                     | 60.3                        |
| Median                                |           | 7.4                 |                     | 7.9                         |
| Min, Max                              |           | 4.4,43.3            |                     | 0.0,53.9                    |
| E AUC0-336h (h*nmol/L)                |           |                     |                     |                             |
| n                                     |           | 131                 |                     | 131                         |
| Geometric mean                        | 2294.2    |                     | 2398.7              |                             |
| Geometric CV (%)                      |           | 44.0                |                     | 39.7                        |
| Arithmetic mean (SD)                  |           | 2495.1 (1030.0)     | 2580.4              | (1069.2)                    |
| CV%                                   |           | 41.3                |                     | 41.4                        |
| Median                                |           | 2388.8              |                     | 2455.6                      |
| Min, Max                              |           | 683.2,6812.5        |                     | 708.2,9284.6                |
| E AUC0-504h (h*nmol/L)                |           |                     |                     |                             |
| n                                     |           | 130                 |                     | 131                         |
| Geometric mean                        | 2459.0    |                     | 2558.0              |                             |
| Geometric CV (%)                      |           | 44.2                |                     | 40.5                        |
| Arithmetic mean (SD)                  |           | 2679.1 (1140.0)     | 2756.9              | (1137.7)                    |
| CV%                                   |           | 42.6                |                     | 41.3                        |
| Median                                |           | 2546.3              |                     | 2613.5                      |
| Min, Max                              |           | 683.2,8418.1        |                     | 722.3,9294.2                |
| E peak (nmol/L)                       |           |                     |                     |                             |
| n                                     |           | 134                 |                     | 132                         |
| Geometric mean                        | 22.6      |                     | 23.2                |                             |
| Geometric CV (%) Arithmetic mean (SD) |           | 41.1 24.3 (9.7)     |                     | 34.1 24.5 (8.3)             |
| CV%                                   |           | 39.7                |                     | 33.8                        |

<div style=\"page-break-after: always\"></div>

| Median               |      | 23.6        |      | 23.4        |
|----------------------|------|-------------|------|-------------|
| Min, Max             |      | 8.7,64.7    |      | 9.0,54.1    |
| ET max (h)           |      |             |      |             |
| n                    |      | 134         |      | 132         |
| Geometric mean       | 45.9 |             | 45.0 |             |
| Geometric CV (%)     |      | 36.9        |      | 35.1        |
| Arithmetic mean (SD) |      | 49.4 (23.3) |      | 47.9 (18.9) |
| CV%                  |      | 47.2        |      | 39.5        |
| Median               |      | 40.1        |      | 44.0        |
| Min, Max             |      | 24.0,215.0  |      | 24.0,144.0  |

PD: Pharmacodynamics; SC: Subcutaneous; IM: Intramuscular; SD: Standard Deviation; CV: Coefficient variation

Ebaseline: Baseline concentration

EAUC0-336: Effect-time curve from time zero to 336 hours postdose

EAUC0-504 Effect-time curve from time zero to 504 hours postdose

Epeak: Maximum effect

ETmax: Time to reach maximum effect

Run Date:14OCT2019

## 2.4.4. Discussion on clinical pharmacology

## Analytical methods

A statement on the application of appropriate GCP standards in the submitted study was provided by the MAH. Upon request, the MAH provided copies of the approval letter from the Midlands Independent Review Board.

During the procedure, the MAH was requested to further clarify the handling and processing of blood samples  to  obtain  the  serum.  This  information  was  provided  and  according  to  standard  laboratory procedures.

The MAH was requested to provide the reports for the ELISA used for measuring BIIB017 and neopterin levels in serum to confirm the acceptability of the methods. The method validation reports for the ELISA used for measuring BIIB017 levels in serum was provided confirming the acceptability of the method. The method validation report for the determination of neopterin was also provided. A minor deviation from the Guideline on bioanalytical method validation was found but no longer pursued as the analysis was done for exploratory purpose only.

For the ELISA to measure serum BIIB017 levels, stability data until 549 days was provided during the procedure and met the required criteria. Hence, the storage period of 212 days of the samples before processing was covered by the tested stability data.

The MAH was requested to clarify the reasons of the 9 samples labelled as 'others' that were re-analysed . The MAH clarified as follows: the LLOQ was not included in the standard curve in these samples due to a %CV or %RE greater than 25%. As a consequence, these samples had a new 'LLOQ' which was the next upper concentration on the standard curve. In the re-analysis, the samples were analysed using the full standard curve in line with the SOP. The clarification is agreed.

## Pharmacokinetics

Based on the results, the exposure of BIIB017 in serum has been demonstrated to be bioequivalent after a single dose administration of 125 μ g BIIB017 either via SC or IM. The point estimate ratio and the 90% CI for AUC0-∞ , AUC0-t and Cmax between SC and IM were 1.09, (1.02 - 1.16); 1.13, (1.06 - 1.21); and 1.08, (0.98 - 1.20), respectively and were within the acceptance range of 0.80 - 1.25.

According to the protocol, for the SC injection, 6 subjects were not included in the statistical analysis for AUC0-∞ due to poor regression of the elimination phase (n=2) and &gt;20% extrapolation in AUC0-∞ (n=4); and 1 subject for the IM injection due to &gt;20% extrapolation in AUC0-∞ . Exclusion if AUC0-t covers less than 80% of AUC0-∞ is not according to the Guideline on the investigation of bioequivalence, section 4.1.8. All subjects should be included. In the sensitivity analysis all subjects were included; hence the

<div style=\"page-break-after: always\"></div>

sensitivity  analysis  already  solved  this  issue.  Moreover,  as  this  application  concerns  a  procedure  to include a new route of administration, AUC0-last was considered a valid parameter to conclude comparable bioavailability between SC and IM route of administration.

Information about PK profiles of Plegridy following IM vs SC administration was included in a dedicated subheading in section 5.2 of the SmPC.

## Pharmacodynamic

Neopterin peak concentrations (Epeak) reached a level of 22.6nmol/L for SC and 23.2nmol/L for IM administration. The Tmax was 40.1hours for SC administration and 44.0hours for IM administration. The overall systemic exposures to neopterin were also similar between the 2 routes of administration; EAUC0336 geometric mean was 2294h*nmol/L for SC administration and 2399h*nmol/L for IM administration. The  EAUC0-504  geometrical  mean  was  2459h*nmol/L  and  2558h*nmol/L  following  SC  and  IM administration, respectively. Therefore, the serum concentration profile of neopterin were comparable between the two routes of administration. Bioequivalence between the SC and IM route of administration could be concluded from a PD perspective.

Results on ETmax, EAUC0-336h and EAUC0-504h from the PD analysis following the SC and the IM injections were included a dedicated subheading in section 5.2 of the SmPC.

## Immunogenicity

There  were  no  immunogenicity  tests  conducted.  Considering  the  limited  exposure  time,  cross  over between route of administration and the low immunogenicity of BIIB017, this is understood. However, the route of administration may impact the immunogenicity. A discussion on the impact of the route of administration on immunogenicity was provided and included in clinical safety section (see 2.6.1 section).

## 2.4.5. Conclusions on clinical pharmacology

The 90% CI for AUC0-∞ , AUC0-t and Cmax between SC and IM were within the acceptance range of 0.80 -1.25. Overall, bioequivalence was shown between SC and IM administration.

The neopterin peak concentration (Epeak), time to neopterin peak concentrations (Tmax) and overall systemic exposures to neopterin were comparable between the two routes of administration. Thus, the serum concentration profile of neopterin were comparable between the two routes of administration and bioequivalence between the SC and IM route of administration could be concluded from a PD perspective.

## 2.5. Clinical efficacy

Plegridy received approval in the European Union on the 18th of July 2014. Hence, efficacy of BIIB017 administered SC is considered established. Bioequivalence of IM and SC administration of BIIB017 was assessed in Study 105HV106 (see clinical pharmacology section above). No new clinical efficacy studies were conducted to support this extension application.

## 2.5.1. Discussion on clinical efficacy

As SC and IM administration was shown to be bioequivalent with regard to PK and PD parameters and profiles, the efficacy results obtained for SC administration can be extrapolated to IM administration.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Conclusions on the clinical efficacy

Efficacy of IM injection of Plegridy was considered demonstrated.

## 2.6. Clinical safety

## Patient exposure

The safety population is defined as all volunteers who were randomized and received at least 1 dose of study treatment. All 136 volunteers enrolled in Study 105HV106 were included in the safety population. ISRs were specifically analysed because of the anticipated decrease of these events in the IM route of administration.

## Adverse events

Throughout the course of the study, every effort was to be made to remain alert to possible adverse event (AEs). If an AE occurred, the first concern was to be the safety of the volunteer. If necessary, appropriate medical intervention was to be provided.

At the signing of the informed consent form, each volunteer was to have been given the names and telephone numbers of study site staff for reporting AEs and medical emergencies. Activities (Version 21.1) and classified as either pre-treatment AEs or treatment-emergent AEs (TEAEs) as follows:

- Pre-treatment AEs were events that started prior to the initial dosing of study treatment in the study.
- TEAEs were events that increased in severity or that were newly developed during Treatment Period 1 or Treatment Period 2. If an AE started (or increases in severity) during a specific Treatment Period, this AE was attributed to the treatment the volunteer was receiving during the Treatment Period.

All analyses of AEs included only TEAEs.

Overall, there were 92 volunteers that reported at least 1 AE after receiving 125 μg BIIB017 SC and 87 volunteers  that  reported  at  least  1  AE  after  receiving  125  μg  BIIB017  IM (Table  4).  All  AEs  were considered  resolved  prior  to  the  end  of  study.  There  were  no  SAEs  reported.  Three  volunteers discontinued study treatment and were withdrawn from the study due to AEs (Table 4).

Table 4: Overall summary of Adverse events - safety population

|                                   | BIB017125 ug SC (N=134) n (%)   | BIIB017125 ug IM (N=132) n (%)   |
|-----------------------------------|---------------------------------|----------------------------------|
| Number of subjects with           |                                 |                                  |
| Any event                         | 92 (68.7)                       | 87 (65.9)                        |
| Severity (a)                      |                                 |                                  |
| Mild                              | 87 (64.9)                       | 83 (62.9)                        |
| Moderate                          | 5 (3.7)                         | 4 (3.0)                          |
| Severe                            | 0                               | 0                                |
| Related event (b)                 | 89 (66.4)                       | 81 (61.4)                        |
| Seriousevent                      | 0                               | 0                                |
| Relatedseriousevent (b)           | 0                               | 0                                |
| Events leading to drug withdrawal | 1 (0.7)                         | 2 (1.5)                          |
| Eventsleading tostudy withdrawal  | 一 (0.7)                         | 2 (1.5)                          |
| Fatal event                       | 0                               | 0                                |

NOTE 1: A subject can appear in more than one category.

(a) Each subject counted once at maximum severity.

(b) Related as assessed by the investigator.

Run Date:

14OCT2019

<div style=\"page-break-after: always\"></div>

The most commonly reported AEs across both treatment periods were headache, chills, pain, injection site  pain,  injection  site  erythema,  and  pyrexia.  The  most  frequently  reported  AE  in  volunteers  that received BIIB017 SC was headache, which was reported by 55 volunteers.

Similarly, 47 volunteers experienced at least 1 AE of headache after receiving BIIB017 IM. The most frequently reported AEs in volunteers that received BIIB017 IM were headache and chills, which were each reported by 47 volunteers. Comparably, 36 volunteers that received BIIB017 SC reported chills. Generalized pain was experienced by more volunteers that received BIIB017 IM, with 29 volunteers reporting at least 1 instance of pain after BIIB017 IM compared to 19 volunteers reporting pain after BIIB017 SC. Injection site erythema was experienced by more volunteers that received BIIB017 SC, with 34 volunteers experiencing at least 1 instance of injection site erythema after BIIB017 SC compared to 3  volunteers  experiencing  injection  site  erythema  after  BIIB017  IM.  A  similar  number  of  volunteers experienced injection site pain across both groups, with 19 volunteers experiencing at least 1 instance after  BIIB017  SC  and  15  volunteers  experiencing  after  BIIB017  IM.  A  similar  number  of  volunteers reported pyrexia across both groups, with 12 volunteers reporting at least 1 instance after BIIB017 SC and 13 volunteers reporting at least 1 instance after BIIB017 IM.

## Analysis by severity

The Investigator assessed the severity of each AE as mild, moderate, or severe.

The majority of volunteers experienced AEs that were mild in severity; however, moderate AEs were recorded for 5 volunteers following administration of 125 μg BIIB017 SC and 4 volunteers following administration of 125 μg BIIB017 IM ( Table 4). The moderate AEs included headache, injection site erythema, otitis externa, and presyncope. No severe AEs were reported.

## Analysis by relationship to Study Treatment

The Investigator assessed the relationship of each AE to study treatment as either related or not related. The number of volunteers reporting study treatment-related AEs were similar between treatments. Of the 92 volunteers that had at least 1 AE following administration of BIIB017 SC, 89 were considered related to the study treatment, and of the 87 volunteers that had at least 1 AE following administration of BIIB017 IM, 81 were considered related to the study treatment (Table 5).

The study-drug related AE with the highest incidence was headache, with a similar number of volunteers reporting the AE after each treatment. Chills was the second highest study drug-related AE, with 36 volunteers reporting at least 1 instance after administration of BIIB017 SC and 46 volunteers reporting at least 1 instance after administration of BIIB017 IM. With the exception of 1 AE of injection site pain, all ISRs were considered related to the study treatment and there was a higher incidence of volunteers reporting ISRs following administration of BIIB017 SC (Table 5).

With the exception of the AEs of presyncope and otitis externa, all other moderate AEs were considered related to the study treatment

Table 5: Adverse Events Related to Study Treatment by System Organ Class and Preferred Term - Safety Population

|                                          | BIIB017 125 ug SC (N=134) n (%)   | BIIB017 125 ug IM (N=132) n (%)   |
|------------------------------------------|-----------------------------------|-----------------------------------|
| Subjects with any TEAEs related to study | 89 (66.4)                         | 81 (61.4)                         |
| General disorders and administration     | 75 (56.0)                         | 71 (53.8)                         |
| site conditions                          |                                   |                                   |
| Chills                                   | 36 (26.9)                         | 46 (34.8)                         |
| Pain                                     | 19 (14.2)                         | 29 (22.0)                         |
| Injection site pain                      | 19 (14.2)                         | 15 (11.4)                         |

<div style=\"page-break-after: always\"></div>

| Pyrexia                                              | 11 (8.2)        | 13 (9.8)         |
|------------------------------------------------------|-----------------|------------------|
| Feeling hot                                          | 7 (5.2)         | 8 (6.1)          |
| Influenza like illness                               | 3 (2.2)         | 3 (2.3)          |
| Injection site erythema                              | 34 (25.4)       | 3 (2.3)          |
| Asthenia                                             | 0               | 2 (1.5)          |
| Injection site reaction                              | 0               | 2 (1.5)          |
| Feeling cold                                         | 1 (0.7)         | 1 (0.8)          |
| Feeling of body temperature change                   | 2 (1.5)         | 1 (0.8)          |
| Injection site induration                            | 4 (3.0)         | 1 (0.8)          |
| Injection site pruritus                              | 11 (8.2)        | 1 (0.8)          |
| Fatigue                                              | 4 (3.0)         | 0                |
| Injection site bruising                              | 2 (1.5)         | 0                |
| Injection site extravasation                         | 1 (0.7)         | 0                |
| Injection site haematoma                             | 1 (0.7)         | 0                |
| Injection site oedema                                | 1 (0.7)         | 0                |
| Injection site rash                                  | 2 (1.5)         | 0                |
| General disorders and administration site conditions |                 |                  |
| Injection site warmth                                | 5 (3.7)         | 0                |
| Nervous system disorders                             | 52 (38.8)       | 54 (40.9)        |
| Headache                                             | 52 (38.8)       | 46 (34.8)        |
| Dizziness                                            | 3 (2.2)         | 8 (6.1)          |
| Somnolence                                           | 1 (0.7)         | 4 (3.0)          |
| Paraesthesia                                         | 1 (0.7)         | 2 (1.5)          |
| Dysgeusia                                            | 1 (0.7)         | 0                |
| Musculoskeletal and connective tissue disorders      | 20 (14.9)       | 20 (15.2)        |
| Pain in extremity                                    | 1 (0.7)         | 6 (4.5)          |
| Myalgia                                              | 5 (3.7)         | 4 (3.0)          |
| Arthralgia                                           | 5 (3.7)         | 3 (2.3)          |
| Back pain                                            | 11 (8.2)        | 3 (2.3)          |
| Joint stiffness                                      | 0               | 1 (0.8)          |
| Limb discomfort                                      | 0               | 1 (0.8)          |
| Muscle spasms                                        | 0               | 1 (0.8)          |
| Musculoskeletal pain                                 | 0               | 1 (0.8)          |
| Musculoskeletal stiffness                            | 0               | 1 (0.8)          |
| Groin pain                                           | 1 (0.7)         | 0                |
| Neck pain                                            | 2 (1.5)         | 0                |
| Gastrointestinal disorders Nausea                    | 9 (6.7) 7 (5.2) | 10 (7.6) 8 (6.1) |
| Vomiting                                             | 2 (1.5)         | 3 (2.3)          |
| Diarrhoea                                            | 0               | 1 (0.8)          |
| Abdominal pain                                       | 1 (0.7)         | 0                |
| Faeces soft                                          | 1 (0.7)         |                  |
| Flatulence                                           | 1 (0.7)         | 0 0              |
| Eye disorders                                        | 4 (3.0)         | 6 (4.5)          |
| Eye irritation                                       | 3 (2.2)         | 2 (1.5)          |
| Photophobia                                          | 0               | 2 (1.5)          |
| Eye pain                                             |                 | 1 (0.8)          |
|                                                      | 1 (0.7)         |                  |
| Vision blurred Metabolism and nutrition disorders    | 0 4 (3.0)       | 1 (0.8) 6 (4.5)  |
| Decreased appetite                                   | 4 (3.0)         | 6 (4.5)          |
| Respiratory, thoracic and mediastinal                | 7 (5.2)         | 3 (2.3)          |
| disorders                                            |                 |                  |
| Nasal congestion                                     | 3 (2.2)         | 2 (1.5)          |
| Cough                                                | 1 (0.7)         | 1 (0.8)          |
| Oropharyngeal pain                                   | 1 (0.7)         | 0                |
| Rhinorrhoea                                          | 2 (1.5)         | 0                |
| Sneezing                                             | 2 (1.5)         | 0                |
| Skin and subcutaneous tissue disorders               | 5 (3.7)         | 2 (1.5)          |
| Rash                                                 | 0               | 1 (0.8)          |
| Sensitive                                            | 1 (0.7)         | 1 (0.8) 0        |
| skin Dermatitis                                      | 2 (1.5)         |                  |
| Erythema                                             | 2 (1.5)         | 0                |

<div style=\"page-break-after: always\"></div>

| Pruritus                    | 2 (1.5)   | 0       |
|-----------------------------|-----------|---------|
| Vascular disorders          | 0         | 2 (1.5) |
| Flushing                    | 0         | 2 (1.5) |
| Cardiac disorders           | 1 (0.7)   | 1 (0.8) |
| Palpitations                | 1 (0.7)   | 1 (0.8) |
| Renal and urinary disorders | 1 (0.7)   | 0       |
| Pollakiuria                 | 1 (0.7)   | 0       |

## NOTEs

1: Events were coded using MedDRA version 22.0.

2: A subject was counted only once within each system organ class, preferred term and treatment-emergent period.

3: System organ class and preferred term are presented in decreasing frequency in the group of BIIB017 125 ug IM.

4: Included in this table are treatment-emergent adverse events.

Run Date:17OCT2019

## Serious adverse event and deaths

There were no deaths, serious AE, or other significant events recorded in this study (Table 4).

## Laboratory findings

Blood chemistry, haematology, and urinalysis samples were collected throughout the study.

Data for haematology, blood chemistry, and urinalysis received from the central laboratory. Out-of-range values were flagged in the listings as high (H) or low (L) for haematology and blood chemistry, and as 'abnormal' for urinalysis. For haematology and blood chemistry, shift tables presenting movement in and out of reference range from period baseline to each scheduled post-baseline visit were provided for each treatment group. Corresponding shift tables (normal versus abnormal) were produced for urinalysis. For post-baseline, only data from scheduled visits were included in the summary tables.

There were no apparent trends in the haematology data for either treatment group. One volunteer was withdrawn from the study due to anaemia (Table 6).

Table 6: Haematology Shift from Baseline - Safety Population

|                                                 | BIIB017 125 ug SC (N=134)   | BIIB017 125 ug SC (N=134)   | BIIB017125ugIM (N=132)   | BIIB017125ugIM (N=132)   |
|-------------------------------------------------|-----------------------------|-----------------------------|--------------------------|--------------------------|
| Shift to Low (a)                                |                             |                             |                          |                          |
| Hematology:Leukocytes                           | 5/130 (3.8)                 |                             | 3/129 (2.3)              |                          |
| Hematology:Neutrophils                          | 5/128 (3.9)                 |                             | 3/129 (2.3)              |                          |
| Hematology:Erythrocytes                         | 1/127(                      | (0.8)                       | 1/124 (0.8)              |                          |
| Hematology:Hemoglobin                           | 6/118                       | (5.1)                       | 3/117                    | (2.6)                    |
| Hematology:Hematocrit                           | 4/122                       | (3.3)                       | 0/123                    |                          |
| Hematology:Platelets                            | 0/131                       |                             | 1/130                    | (0.8)                    |
| Hematology:Ery. Mean Corpuscular Hemoglobin     | 2/112                       | (1.8)                       | 2/110                    | (1.8)                    |
| Hematology:Ery.Mean CorpuscularHGBConcentration | 2/129                       | (1.6)                       | 4/128 (3.1)              |                          |
| Hematology: Ery. Mean Corpuscular Volume        | 1/119                       | (0.8)                       | 1/118 (0.8)              |                          |
| Shift to High (b)                               |                             |                             |                          |                          |
| Hematology: Leukocytes                          | 1/131 (0.8)                 |                             | 0/131                    |                          |
| Hematology:Lymphocytes                          | 8/128 (6.3)                 |                             | 4/126 (3.2)              |                          |
| Hematology:Neutrophils                          | 1/131                       | (0.8)                       | 0/131                    |                          |
| Hematology:Monocytes                            | 2/130                       | (1.5)                       | 2/129                    | (1.6)                    |
| Hematology:Eosinophils                          | 0/130                       |                             | 1/129                    | (0.8)                    |
| Hematology:Erythrocytes                         | 0/128                       |                             | 1/130                    | (0.8)                    |
| Hematology:Platelets                            |                             | 16/124 (12.9)               |                          | 17/122 (13.9)            |
| Hematology: Ery. Mean Corpuscular Volume        | 1/127                       | (0.8)                       | 1/129                    | (0.8)                    |

NOTE 1: Entries are number post-baseline shifts/number at risk (percentage).

(a) Shift to low includes normal to low, high to low, and unknown to low.

(b) Shift to high includes normal to high, low to high, and unknown to high.

Run Date: 14OCT2019

There were no trends in the mean blood chemistry data for either treatment group. One volunteer was withdrawn  from  the  study  due  to  physician  decision  after  elevated  liver  function  tests,  creatine phosphokinase,  and  creatine.  A  second  volunteer  was  withdrawn  for  blood  creatine  phosphokinase increased (Table 7).

<div style=\"page-break-after: always\"></div>

Table 7: Blood Chemistry Shift from Baseline - Safety population

|                                       | BIIB017125 ug SC (N=134)   | BIIB017125 ug SC (N=134)   | BIIB017 125 ug IM (N=132)   | BIIB017 125 ug IM (N=132)   |
|---------------------------------------|----------------------------|----------------------------|-----------------------------|-----------------------------|
| Shift to Low (a)                      |                            |                            |                             |                             |
| Chemistry: Creatinine                 | 0/123                      |                            | 3/124 (2.4)                 |                             |
| Chemistry: Carbon Dioxide             | 0/124                      |                            | 1/125 (0.8)                 |                             |
| Chemistry: Calcium                    | 1/130                      | (0.8)                      | 0/130                       |                             |
| Chemistry: Urate                      | 1/128 (0.8)                |                            | 1/128                       | (0.8)                       |
| Shift to High (b)                     |                            |                            |                             |                             |
| Chemistry:AlanineAminotransferase     | 6/128 (4.7)                |                            | 6/124 (4.8)                 |                             |
| Chemistry: Aspartate Aminotransferase | 1/129                      | (0.8)                      | 0/130                       |                             |
| Chemistry:AlkalinePhosphatase         | 3/128                      | (2.3)                      | 2/129                       | (1.6)                       |
| Chemistry:Bilirubin                   | 4/131                      | (3.1)                      | 2/131                       | (1.5)                       |
| Chemistry: Gamma Glutamyl Transferase | 3/128                      | (2.3)                      | 1/126                       | (0.8)                       |
| Chemistry: Creatinine                 | 5/131                      | (3.8)                      | 2/131                       | (1.5)                       |
| Chemistry: Sodium                     | 7/127                      | (5.5)                      | 10/129                      | (7.8)                       |
| Chemistry:Potassium                   | 2/121                      | (1.7)                      | 0/121                       |                             |
| Chemistry: Chloride                   | 0/127                      |                            | 3/127                       | (2.4)                       |
| Chemistry: Carbon Dioxide             | 3/128                      | (2.3)                      | 1/127                       | (0.8)                       |
| Chemistry: Glucose                    | 3/97                       | (3.1)                      | 1/101                       | (1.0)                       |
| Chemistry: Calcium                    | 3/127                      | (2.4)                      | 3/127                       | (2.4)                       |
| Chemistry: Phosphate                  | 9/124 (7.3)                |                            | 12/122                      | (9.8)                       |
| Chemistry: Protein                    | 2/130 (1.5)                |                            | 2/131                       | (1.5)                       |

NOTE 1: Entries are number post-baseline shifts/number at risk (percentage).

(a) Shift to low includes normal to low, high to low, and unknown to low.

(b) Shift to high includes normal to high, low to high, and unknown to high.

Run Date:

14OCT2019

A summary of shifts from baseline in urinalyses data is presented in Table 8.

Table 8: Urinalysis shift from baseline - Safety population

|                              | BIB017 125 ug SC (N=134)   | BIB017 125 ug IM (N=132)   |
|------------------------------|----------------------------|----------------------------|
| Shift to Abnormal (c)        |                            |                            |
| Urinalysis: Occult Blood     | 3/123 (2.4)                | 4/126 (3.2)                |
| Urinalysis: Protein          | 1/130 (0.8)                | 4/131 (3.1)                |
| Urinalysis: Nitrite          | 2/130 (1.5)                | 2/129 (1.6)                |
| Urinalysis:LeukocyteEsterase | 7/126 (5.6)                | 11/129 (8.5)               |

NOTE 1: Entries are number post-baseline shifts/number at risk (percentage).

(a) Shift to low includes normal to low, high to low, and unknown to low.

(b) Shift to high includes normal to high, low to high, and unknown to high.

Run Date:

14OCT2019

## Vital Sign Measurement, Physical Examination Findings, and Other Observations Related to Safety

## Vital Sign Measurements

For each treatment group, observed measurements of vital signs (temperature, respiratory rate, pulse, systolic blood pressure, and diastolic blood pressure) and change from period baseline were summarized by visit using descriptive statistics. The abnormalities were consistent between treatment groups. There were no abnormal vital signs data that were associated with any clinical symptoms. There were no apparent trends in the mean vital signs data for either treatment group.

Physical Examination Findings &amp; Patients Health Questionnaire (depression module)

Any clinically significant physical examination findings were reported as AEs and presented in above section.

The majority of volunteers responded 'Not at all' to the PHQ-9 questions at all timepoints. Sporadic responses other than 'Not at all' were recorded, none of which were considered clinically relevant.

<div style=\"page-break-after: always\"></div>

## Electrocardiograms

One volunteer had an abnormal electrocardiogram that was considered a clinically significant AE and resulted in study treatment withdrawal and withdrawal from the study.

## Immunological events

Antibody status was not tested as no unusual PK or safety findings were observed.

## Safety in special populations

N/A

## Safety related to drug-drug interactions and other interactions

N/A

## Discontinuation due to adverse events

One volunteer discontinued study treatment and was withdrawn from the study after receiving 125 μg BIIB017 SC (blood creatinine phosphokinase increased), and 2 volunteers discontinued study treatment and were withdrawn from the study after receiving 125 μg BIIB017 IM (a naemia and tachycardia).

## Post marketing experience

N/A

## 2.6.1. Discussion on clinical safety

Generally, the reported adverse events was comparable between the two routes of administration. The SC  administration  has  a  higher  frequency  of  the  following  ISR;  induration,  pruritus,    bruising, extravasation, haematoma, oedema and rash, compared to the IM group. However, pain in extremity, limb discomfort, muscle spasms, musculoskeletal pain and musculoskeletal stiffness were reported with a higher frequency in the IM group compared to the SC group. This is not unexpected, as these AEs are all  related  to  the  route  of  administration.  Information  about  commonly  reported  AEs  across  both treatment periods together with AEs reported for the SC arm only and the IM arm only were presented in section 4.8 of the SmPC.

The  laboratory  test  also  showed  a  comparable  frequency  of  shift  between  the  two  routes  of administration. However, urinalysis shows a higher frequency in shift to abnormal values for protein and leukocyte esterase following IM administration compared to SC administration. The MAH's position was that differences in urine analysis were not statistically significant and may be chance finding or related to the first or midstream catch as the results did not lead to renal adverse events. This rationale is not fully agreed as it should be noted that the shift to abnormal is 3 times higher occurred after a single administration. Longer exposure may have resulted in the occurrence of renal adverse events. As it cannot be excluded whether the findings were chance finding, related to the first or midstream catch or indeed related to the route of administration, the higher incidence of shift to abnormal was included in the section 4.8 of the SmPC as follows: 'Abnormal urine protein was reported in 1/130 (0.8%) for the SC route of administration and 4/131 (3.1%) in the IM group without any associated adverse drug reactions'.

The shift in vital signs occurred with comparable frequency in both routes of administration.

<div style=\"page-break-after: always\"></div>

No immunological tests were performed; however, the route of administration may have an impact on the immunogenicity. Therefore, the MAH was requested to discuss the potential impact of the route of administration on immunogenicity. The MAH submitted comparative data on immunogenicity following SC and IM administration from Minagar et al 2008, Perini et al 2001, Ross et al 2000 and White et al 2016. As these studies also included immunogenicity as an outcome measure, the duration is much longer (6 months - 3 years) as compared to the bioequivalence study with a range of 27 days. This allows a valid conclusion on immunogenicity.

The data from Minagar et al concerned the studies with INF-beta-1a (without PEG) and showed that 19% of the patients on SC IFN-beta-1a 44 μg three times per week tested positive for N abs (Neutralizing antibodies) at both Month 0 and Month 6, whereas none of those on IM IFN-beta1a 30 μg once weekly were NAbs positive. Perini et al examined the role of dosage, route and frequency of administration of clinical grade interferon-beta preparations on immunogenicity. The findings from this study suggest that treatment  with  IFN-beta-1a  IM  was  the  least  immunogenic  treatment,  i.e.  INF-beta-1a  was  less immunogenic as compared to IFN -beta-1b, and IM administration was less immunogenic compared to SC administration. In patients treated with SC IFN-beta-1b, NAbs levels peaked 3 to 9 months after therapy initiation, and declined to pre-therapy levels in some patients after 3 years. Similar results were reported by Ross et al 2000. Data from White et al 2016 included an analysis of anti-PEG anti body formation following SC administration at 2 and 4 week interval, to characterise the immunogenic profile of the IFN portion and the PEG moiety of PEG-IFN. There was no difference between the PEG antibody formation following a 2 week or 4 week treatment interval. The authors concluded that the low incidence of immunogenicity, including extremely low frequency of anti-peginterferon NAbs developing at high titre levels,  means  that  few  patients  are  at  risk  of  experiencing  impaired  efficacy  during  treatment  with peginterferon beta-1a due to immunogenicity.

These data concern data from other INF-beta-1a products and were therefore considered circumstantial. However, it may be concluded that the immunogenicity following the route of administration is the same or lower as compared to the SC administration i.e. less than 1%.

## 2.6.2. Conclusions on the clinical safety

Overall, the safety profile appears to be comparable between the two routes of administration. Some adverse events occur more frequently in one group compared to the other, however, these adverse events are generally related to the IM route of administration.

## 2.7. Risk Management Plan

## Safety concerns

Table 9: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                           |
|------------------------------|------------------------------------------------------|
| Important identified risks   | None                                                 |
| Important potential risks    | None                                                 |
| Missing information          | • Use during second and third trimester of pregnancy |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

## Table 10: Ongoing and planned additional pharmacovigilance activities

| Study name and description Study Status                                                                                                                                                                                   | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Safety concern(s) addressed                                                                                                                                                                                               | Milestones                                                                                                                                                                                                                | Due dates                                                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                                                        | Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities that are conditions of the marketing authorisation                                                                                                 |
| None                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |
| Category 2 - Imposed mandatory additional pharmacovigilance activities that are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities that are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                                                                                                                                                                                                                                                                        | Category 2 - Imposed mandatory additional pharmacovigilance activities that are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities that are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities that are specific obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| None                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                             |
| Drug utilization study in pregnancy (exposure in second and third trimester) • Status: Planned                                                                                                                            | First stage: • Evaluate interferon-beta utilization among pregnant women in MS in Sweden and Finland at 3 and, if needed, 5 years following label implementation using aggregate level data • Evaluate trends in DU patterns in the target population (second and third trimester) before and after label implementation. • Evaluate the feasibility of conducting a pregnancy outcomes study Second stage: • If feasible, conduct a pregnancy outcomes study on patients exposed during second and third trimester using individual level data. | • Use during second and third trimester of pregnancy                                                                                                                                                                      | First stage: • Drug utilisation study report 3 years after label implementation • If needed, Drug utilisation study report 5 years after label implementation                                                             | First stage: • Drug utilisation study report 3 years after label implementation • If needed, Drug utilisation study report 5 years after label implementation                                                             |

## Risk minimisation measures

## Table 11: Risk Minimization Activities and Pharmacovigilance Activities by Safety Concern

| Safety concern                                       | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                                                                                                                                                                 |
|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks                           | Important identified risks                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Important identified risks                                                                                                                                                                                                   |
| None                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                              |
| Important potential risks                            | Important potential risks                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Important potential risks                                                                                                                                                                                                    |
| None                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                              |
| Areas of missing information                         | Areas of missing information                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Areas of missing information                                                                                                                                                                                                 |
| • Use during second and third trimester of pregnancy | Routine risk minimisation measures: • Information in Section 4.6 of the SmPC describing the paucity of data in relation to drug exposure during the second and third trimester of pregnancy Other routine risk minimisation measures beyond the Product Information: Legal status: Prescription only medicine. Use restricted to physicians experienced in the treatment of MS Additional risk minimisation measures: • No additional risk minimisation measures are proposed. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Drug utilization study in pregnancy (exposure in second and third trimester) |

<div style=\"page-break-after: always\"></div>

## Conclusion

The CHMP and PRAC considered that the risk management plan version 5.2 is acceptable.

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

## 2.9.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Plegridy solution for subcutaneous injection in pre-filled syringe. The bridging report submitted by the MAH has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Plegridy is an interferon beta-1a with a prolonged response (due to PEG conjugation) indicated in adult patients for the treatment of RRMS, the most common phenotype of MS. In MS, an immune-mediated inflammatory activity of the CNS leads to destruction of the myelin sheath and axonal injury.

## 3.1.2. Available therapies and unmet medical need

There  is  no  cure  available  for  MS.  Therapies  for  MS  include  treatment  for  relapses,  symptomatic treatments and DMD. There are several DMD for MS including other beta interferons (IFN β) (Avonex, Betaferon and Rebif) which are available for either SC or IM injection.

Plegridy is an interferon beta-1a with a prolonged response (due to PEG conjugation). It is indicated in adult patients for the treatment of relapsing-remitting multiple sclerosis. The recommended dose of Plegridy  is  125 micrograms  injected  SC  every  2 weeks.  The  product  may  be  self-administered  by patients. The product is available as a 63, 94 and 125 micrograms strength, both in a pre-filled syringe

<div style=\"page-break-after: always\"></div>

and a pre-filled pen. The lower strengths are used for dose titration at the start of treatment, to prevent flu-like symptoms.

The current application concerns an extension application. The MAH proposes to add IM injection to offer patients  an  alternative  route  of  administration  with  fewer  injection  site  reactions  as  compared  to subcutaneous injection.

A new pre-filled syringe has been developed for this purpose. The syringe contains 125 micrograms of peginterferon beta-1a. The dose can be limited to 63 micrograms and 94 micrograms with the use of titration clips.

## 3.1.3. Main clinical study

The  development  program  consisted  of  1  open-label,  multicentre,  2-period  crossover  study  with  a primary objective of assessing the bioequivalence of BIIB017 administered by SC and IM injection in 136 healthy volunteers. Bioequivalence was examined using PK parameters and assessing the safety and tolerability of SC administration as compared with IM administration of BIIB017 in healthy volunteers. Exploratory objectives were to evaluate the PD parameters, i.e. neopterin serum concentration, of SC administration  as  compared  with  IM  administration  in  healthy  volunteers.  The  presence  and  titre  of binding antibodies to the pegylated and IFN β -1a components of BIIB017 was also to be evaluated in case of unusual PK or safety findings.

The low doses (63 and 94 μg) will be administered by the u se of titration clip devices. These titration clip devices can administer the required dose (1/2 and 3/4 dose) and are similar to titration clips already available for other products.

## 3.2. Favourable effects

AUC0-∞ , AUC0-t and Cmax were 173695 pg/ml/h, 163615 pg/ml/h and 1459 pg/ml for the SC route of administration, and 185645pg/ml/h and 180798pg/h and 1517pg/ml for the IM route of administration. The point estimate ratio and the 90% CI for AUC0-∞ , AUC0-t and Cmax between SC and IM were 1.09 (1.021.16); 1.13 (1.06-1.21); and 1.08 (0.98-1.20), respectively.

The  time  to  neopterin  peak  concentrations  (Tmax)  was  40.1hours  and  44.0hrs  following  SC  and  IM administration, respectively. The neopterin peak concentration (Epeak) were 22.6nmol/L for SC and 23.2nmol/L for IM administration. The median overall systemic exposures (EAUC0-504h) to neopterin were 2546h*nmol/L and 2613h*nmol/L for SC and IM administration, respectively.

## 3.3. Uncertainties and limitations about favourable effects

There are no relevant uncertainties and limitations related to favourable effects.

## 3.4. Unfavourable effects

The following TEAEs were reported with &gt;2% difference between the two routes of administration for the SC vs IM respectively: Chills (26.9% vs 34.8%), pain (14.2% vs 22.0%), injection site pain (14.2% vs 11.4%), injection sit erythema (25.4% vs 2.3%), headache (38.8% vs 34.8%), dizziness (2.2% vs 6.1%), backpain (8.2% vs 2.3%).

<div style=\"page-break-after: always\"></div>

The following AEs were reported in the SC treatment arm only: injection site bruising (1.5%), injection sit extravasation (0.7%), injection site haematoma (0.7%), injection site oedema (0.7%) and injection site rash (1.5%)

The following AEs were reported in the IM treatment arm only: joint stiffness limb discomfort, muscle spasms, musculoskeletal pain, musculoskeletal stiffness. All with a frequency of 0.8%.

Urinalysis shows a shift to abnormal values for protein for 4/131 (3.1%) following IM administration compared to 1/130 (0.8%) following SC administration.

## 3.5. Uncertainties and limitations about unfavourable effects

The bioequivalence study was not appropriate to study immunogenicity as it was too short. However, circumstantial evidence submitted by the MAH, i.e. data from other INF beta-1a products, shows that the immunogenicity following IM administration is lower than that following the SC route.

It is unclear if the shift to abnormal values for protein is a chance finding, related to the first or midstream collection or indeed related to the route of administration.

## 3.6. Effects Table

Table 12 Effects Table for Plegridy IM

| Effect                     | Short Description                                                                            | Unit                 | SC                                                          | IM                                                       | Uncertainties/ Strength of evidence                                                | Ref.                 |
|----------------------------|----------------------------------------------------------------------------------------------|----------------------|-------------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------------------------------------|----------------------|
| Favourable Effects         | Favourable Effects                                                                           | Favourable Effects   | Favourable Effects                                          | Favourable Effects                                       | Favourable Effects                                                                 | Favourable Effects   |
| AUC 0- ∞                   | AUC from hr 0 extrapolated to infinity                                                       | pg/ml/h              | 173695                                                      | 185645                                                   | SoE : ratio (90% CI) 1.09 (1.2-1.16) Unc : six subjects excluded                   | 105HV106             |
| AUC 0-t                    | AUC from administration to last observer concentration at time t                             | pg/ml/h              | 163615                                                      | 180798                                                   | SoE: ratio (90% CI) 1.13 (1.06-1.21)                                               | 105HV106             |
| C max                      | Maximum plasma concentration                                                                 | pg/ml                | 1459                                                        | 1517                                                     | SoE: ratio (90% CI) 1.08 (0.98-1.2)                                                | 105HV106             |
| T max                      | Time to maximum effect (median)                                                              | h                    | 40.1                                                        | 44                                                       |                                                                                    | 105HV106             |
| Epeak E AUC0-504h          | Peak concentration (median) Overall exposure (median)                                        | nmol/L h*nmol/L      | 23.6 2546                                                   | 23.4 2613                                                |                                                                                    | 105HV106 105HV106    |
| Unfavourable Effects       | Unfavourable Effects                                                                         | Unfavourable Effects | Unfavourable Effects                                        | Unfavourable Effects                                     | Unfavourable Effects                                                               | Unfavourable Effects |
| TEAEs with >2% differenc e | Chills Pain ISR pain ISR erythema Headache Dizziness Backpain                                | n (%)                | 36(26.9) 19(14.2) 16(14.2) 34(25.4) 52(38.8) 3(2.2) 11(8.2) | 46(34.8) 29(22.0) 15(11.4) 3(2.3) 46(34.8) 8(6.1) 3(2.3) |                                                                                    | 105HV106             |
| TEAEs in SC only           | ISR bruising ISR extravasation ISR haematoma ISR oedema ISR rash (1.5%)                      | n (%                 | 2 (1.5%) 1 (0.7%) 1 (0.7%) 1 (0.7%) 2 (1.5%)                |                                                          |                                                                                    | 105HV106             |
| TEAEs in MI only           | Joint stiffness Limb discomfort Muscle spasms Musculoskeletal pain Musculoskeletal stiffness | n (%)                |                                                             | 1(0.8) 1(0.8) 1(0.8) 1(0.8) 1(0.8)                       |                                                                                    | 105HV106             |
| Immuno genicity            |                                                                                              |                      | low                                                         | unknown                                                  | Unc : not examined. Circumstantial evidence indicates lower frequency following SC | 105HV106             |

<div style=\"page-break-after: always\"></div>

| Effect      | Short Description                                              | Unit                      | SC                        | IM                         | Uncertainties/ Strength of evidence                                 | Ref.     |
|-------------|----------------------------------------------------------------|---------------------------|---------------------------|----------------------------|---------------------------------------------------------------------|----------|
|             |                                                                |                           |                           |                            | administration                                                      |          |
| Urinalysi s | Protein shift to abnormal Leukocyte esterase shift to abnormal | Shift/num ber at risk (%) | 1/130 (0.8%) 7/126 (5.6%) | 4/141 (3.1%) 11/129 (8.5%) | Unc : could be chance finding or related to route of administration | 105HV106 |

ISR: Injection site reaction; TEAEs: Treatment-related adverse event; IM: Intramuscular; SC: Subcutaneous; Unc: uncertainties; SoE: strength of evidence.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The active substance is the same for both the IM and SC formulation. The main difference is the route of administration. The MAH showed that the point estimates and 90% CI of the PK parameters (AUC0-∞ , AUC0-t and Cmax) for between SC and IM were within the acceptance range of 0.80 -1.25. Neopterin levels,  a  well-known  PD  marker  for  INF-B,  were  comparable  in  SC  and  IM  administration,  thus bioequivalence between the SC and IM route of administration could be concluded from a PK and PD perspective.

The dose of 125μg used in the study was the most appropriate dose to examine the bioequivalence as this is the dose required for therapy.

The  frequency  and  reported  type  of  AE  were  generally  comparable  between  the  two  routes  of administration.  There  was  a  higher  frequency  of  ISR  reported  for  the  SC  administration.  IM administration let to occurrences of pain in extremity, limb discomfort, muscle spasms, musculoskeletal pain and musculoskeletal stiffness. These findings were not unexpected as they are all related to the route of administration. Although immunogenicity was not evaluated in the bioequivalence study, the MAH provided a literature review supporting that immunogenicity following IM administration is expected to be lower than that following the SC route. The higher incidence of proteinuria required an SmPC amendment i.e. 'Abnormal urine protein was reported in 1/130 (0.8%) for the SC route of administration and 4/131 (3.1%) in the IM administration.'

## 3.7.2. Balance of benefits and risks

In the present procedure, the MAH has shown PK and PD bioequivalence between Plegridy IM and SC administration. Efficacy of IM injection of Plegridy was considered demonstrated.

No new safety signals were raised. AEs were considered clinically manageable and generally comparable between the two routes of administration with fewer ISR as compared to SC injection, which is considered a benefit for the patients.

Therefore, the favourable effects of Plegridy IM outweigh the risks

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable

## 3.8. Conclusions

Based on the review of the submitted data, the IM administration of Plegridy is considered bioequivalent

<div style=\"page-break-after: always\"></div>

to SC administration of Plegridy. Therefore, a benefit/risk balance comparable to the SC administration of Plegridy can be concluded. The overall B/R is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, clinical pharmacology and safety, the CHMP considers by consensus that the benefit-risk balance of, Plegridy 125 micrograms solution for injection in pre-filled syringe for intramuscular use, is favourable in the following indication:

Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.

The CHMP therefore recommends the extension(s) of the marketing authorisation for Plegridy subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal  product  subject  to  restricted  medical  prescription  (see  Annex  I:  Summary  of  Product Characteristics, section 4.2).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.